Company news

Xencor, Inc. news in 2025

Xencor, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies

December 8, 2025

Xencor to Participate at Upcoming Investor Conferences

November 9, 2025

Xencor Reports Third Quarter 2025 Financial Results

November 4, 2025

Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

October 23, 2025

Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

October 20, 2025

Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 13, 2025

Xencor Reports Second Quarter 2025 Financial Results

August 6, 2025

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

July 30, 2025

Xencor Reports First Quarter 2025 Financial Results

May 6, 2025

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

April 28, 2025

Xencor Appoints Todd Simpson to Board of Directors

March 12, 2025

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

February 26, 2025

Decks in 2025